The estimated Net Worth of Lynn A. Tetrault is at least $824 millier dollars as of 9 September 2024. Mrs. Tetrault owns over 20,700 units of Neogenomics stock worth over $334,371 and over the last 9 years she sold NEO stock worth over $305,609. In addition, she makes $183,633 as Lead Independent Director at Neogenomics.
Lynn has made over 14 trades of the Neogenomics stock since 2015, according to the Form 4 filled with the SEC. Most recently she exercised 20,700 units of NEO stock worth $244,674 on 9 September 2024.
The largest trade she's ever made was exercising 20,700 units of Neogenomics stock on 9 September 2024 worth over $244,674. On average, Lynn trades about 3,671 units every 103 days since 2015. As of 9 September 2024 she still owns at least 20,501 units of Neogenomics stock.
You can see the complete history of Mrs. Tetrault stock trades at the bottom of the page.
Lynn A. Tetrault serves as Lead Independent Director of the Company. Mrs. Lynn A. Tetrault has been named Lead Independent Director of the Board of Directors, effective July 15, 2020. Ms. Tetrault has served on our Board of Directors since June 2015 and is Chair of the Compensation Committee. She is founder of Anahata Leadership, an advisory firm focused on supporting the leadership effectiveness of executive women. Ms. Tetrault has more than 25 years of experience in the healthcare sector. She worked from 1993 to 2014 with AstraZeneca, PLC, most recently on its global executive team as Executive Vice President of Human Resources and Corporate Affairs from 2007 to 2014. Prior to AstraZeneca, Ms. Tetrault practiced healthcare and corporate law at Choate, Hall and Stewart in Boston. Ms. Tetrault serves on the Strategic Advisory Board of The Simmons University Institute for Inclusive Leadership and on the Board of WHAM (Women's Health Access Matters). Ms. Tetrault has an undergraduate degree from Princeton University and a J.D. from the University of Virginia Law School.
As the Lead Independent Director of Neogenomics, the total compensation of Lynn Tetrault at Neogenomics is $183,633. There are 10 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of $3,648,730.
Lynn Tetrault is 57, she's been the Lead Independent Director of Neogenomics since 2020. There are 12 older and 13 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
Lynn's mailing address filed with the SEC is 222 BERKELEY STREET,, 12TH FLOOR, BOSTON, MA, 02116.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van et Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: